Introduction {#sec1}
============

It is known that patients with knee osteoarthritis (OA) exhibit muscle weakness[@bib1; @bib2; @bib3; @bib4; @bib5; @bib6; @bib7; @bib8; @bib9], which is one of the most frequent and earliest reported symptoms associated with knee OA[@bib10]. It primarily affects the quadriceps muscle with little or no evidence of hamstring weakness[@bib4], resulting in a reduced quadriceps to hamstring (Q/H) ratio[@bib11].

Historically, muscle weakness has been considered a secondary effect in knee OA, resulting from disuse of the affected joint due to the presence of pain and/or inflammation, and therefore has received little attention with regards to its involvement in the initiation or progression of OA. However, there is evidence which suggests that quadriceps weakness may precede the onset of radiographic evidence of OA and pain[@bib2], and be directly involved in its pathogenesis[@bib6]. Firstly, quadriceps weakness is reported in those patients with radiographic signs of knee OA in the absence of pain, suggesting that the muscle weakness is unlikely to be due to disuse of a painful joint[@bib12]. Secondly, quadriceps weakness is noted in a number of patient groups who are susceptible to developing knee OA, for example patients who have gait abnormalities resulting in increased knee loading[@bib13], patients with anterior cruciate ligament (ACL) insufficiencies[@bib14] and most commonly patients who have undergone partial meniscectomy (MNX) surgery as a treatment of medial meniscal tears[@bib15]. Initially, patients who have undergone MNX have marked muscle weakness of the ipsilateral limb in the absence of manifest OA[@bib1; @bib16]. However, at long-term follow-up, meniscectomised patients have an elevated incidence of OA (odds ratio = 10), compared to age and sex matched subjects with no history of meniscal injury[@bib17]. In these patient groups, quadriceps dysfunction is noted prior to any radiographic evidence of OA, again suggesting that the quadriceps dysfunction reported in knee OA is unlikely to be solely due to disuse atrophy.

Whether a strong quadriceps muscle can also be a protective factor in the initiation of OA is perhaps more debatable. A study examining the incidence of OA at a 5-year follow-up in subjects with no radiographic evidence of OA at baseline, found that those subjects who developed OA had weaker quadriceps strength at baseline[@bib18]. Conversely, a recent longitudinal study conducted by Segal, NA and colleagues found that although extensor strength was reduced with increasing KL grade for tibiofemoral OA at baseline, neither strength nor normal Q/H ratio was protective against the development of incident radiographic OA. However, of interest, increased extensor strength *was* protective against the development of incident symptomatic whole knee OA albeit this was restricted to female participants once corrected for knee pain at baseline[@bib19].

There is also controversy with regards quadriceps strength and disease progression in individuals with established knee OA. Whilst the assessment of patients with established knee OA showed that a strong quadriceps muscle was protective for cartilage loss at the lateral compartment of the patellofemoral joint over a 30-month period in one study[@bib20], other studies have found this protective effect to be limited to females only[@bib3] and one study found a detrimental effect in malaligned and lax knees[@bib21].

Despite this, a number of studies have shown that exercises aimed at improving quadriceps function have beneficial symptomatic effects in knee OA patients[@bib7; @bib8; @bib22; @bib23; @bib24; @bib25; @bib26; @bib27; @bib28]. For example, the impact of both high and low resistance training on subjects with knee OA has been recently investigated, where it was reported that improved quadriceps function was associated with a reduction in knee pain and increased physical ability[@bib24]. Similarly, strength training (ST) and balance exercises have also been shown to significantly reduce knee pain and improve physical ability[@bib23]. To date, only one randomised controlled trial evaluating the effects of ST programs on the onset and progression of knee OA has been conducted[@bib7]. Here, patients with established knee OA undergoing three sessions of ST per week had reduced joint space narrowing (JSN) at 30-month follow-up compared with those patients undertaking range of motion (ROM) exercises for the same duration. However, patients who were radiographically normal at baseline exhibited a slightly elevated incidence of JSN than those undertaking ROM exercises.

Improving skeletal muscle strength and functional performance through intensive exercise regimes is often inappropriate or contra-indicated for the majority of OA patients who are elderly, overweight, co-morbid and may be frail. β2-adrenergic agonists, such as clenbuterol, have potent anabolic effects on skeletal muscle, inducing increases in lean mass and contractile speed[@bib29] similar to those observed through targeted ST protocols. Therefore, developing a pharmacological agent that is able to mimic intensive exercise regimes by improving muscle function in knee OA patients could provide a plausible route through which to modify the course of OA during both initiation, and progression[@bib2; @bib7; @bib30].

Morphological studies suggest that the muscle dysfunction in knee OA is due, in part, to atrophy of the muscle fibres. A recent study noted that all patients assessed with knee OA presented with atrophy of type II fast-twitch muscle fibres, whilst less than one third of the patients presented with atrophy of type I slow-twitch muscle fibres[@bib31] as assessed by histochemical staining. This suggests that quadriceps dysfunction in knee OA is most commonly associated with atrophy of fast-twitch type II muscle fibres, an observation supported by previous histochemical studies[@bib32]. Therefore, a pharmacological agent that is able to selectively promote hypertrophy of skeletal muscle fibres, thus increasing muscle mass warrants investigation in an OA context. In this context, clenbuterol is a synthetic β2-adrenergic agonist, the action of which mimics adrenaline. Clenbuterol induces muscle hypertrophy *via* the stimulation of β-adrenoceptors and the subsequent activation of downstream signalling pathways[@bib33]. In addition to marked increases in skeletal muscle mass in a number of animal models of muscle wasting[@bib34; @bib35; @bib36; @bib37], clenbuterol has also been shown to induce slow to fast fibre transitions in certain muscle groups[@bib36; @bib38].

To facilitate the identification of such an agent we explored whether a known modulator of muscle mass and muscle fibre type, the β2-adrenergic agonist, clenbuterol, was able to modify the severity of joint disease, assessing joint pathology and behavioural pain, in a MNX-induced rodent model of OA.

Materials and methods {#sec2}
=====================

Animals and housing {#sec2.1}
-------------------

A total of 35 male Lewis rats (280.4 g ± 1.7) were housed in groups of six with free access to food and standard laboratory chow. Animals were subcutaneously administered the potent β~2~-adrenergic agonist clenbuterol HCl at a dosage of 1.5 mg/kg/day bodyweight (*n* = 15), or saline vehicle (*n* = 20) for a total of 14 days. Following pre-treatment, five animals from each group were sacrificed to assess the immediate effects of clenbuterol. The remaining animals underwent either MNX surgery (clenbuterol pre-treated *n* = 10; saline pre-treated *n* = 10) or a sham control surgical procedure (saline pre-treated *n* = 5). Clenbuterol hydrochloride (C~12~H~18~Cl~2~N~2~O·HCl MW 277.2) was sourced from Alexis pharmaceuticals, UK as a stock powder. A 1.5 mg/ml (w/v) solution was prepared in sterile physiological saline and aliquots stored at −20°C. A fresh aliquot of compound was thawed for each day of dosing to minimise any degradation over the course of the study. All sample size calculations were based on variation in surgical technique, determined from previous studies conducted by the same surgeon (un-published observations).

Surgical induction of OA (MNX) {#sec2.2}
------------------------------

All *in vivo* procedures were carried out in accordance to the UK Animals (Scientific Procedures) Act 1986. OA was induced *via* MNX surgery as previously described[@bib39]. All surgery was performed under 3.5% Isofluorane inhalational anaesthetics. Rats received a dose of Cefalexin antibiotic (0.03 ml/100 g Ceporex oral drops) 1 h prior to and 12, 24, and 36 h post surgery. Animals also received subcutaneous analgesia (0.01 ml/100 g Rimadyl, Pfizer) on the induction of anaesthesia and 24 h post surgery. A small incision was made longitudinally down the medial side of the knee and a cauteriser was used to work through both the connective tissue and muscle layers until the medial collateral ligament, anchoring the medial meniscus to the tibial (TIB) plateau, was identified. The ligament was grasped at the TIB end and cut until fully transected. The ligament was then transected again at the femoral (FEM) end to remove the portion overlying the meniscus. The meniscus was freed from the fine connective tissue, allowing a full thickness, medial meniscal transection. Sham animals underwent the same surgical procedure with the omission of medial meniscal transection.

Weight bearing assessment {#sec2.3}
-------------------------

Weight bearing, as a surrogate of behavioural joint pain, was measured using an incapacitance meter (Linton Instrumentation, UK) as described previously[@bib40]. The operator was blinded to both the pre-treatment regime and the previous measurements. The difference in weight borne by the two hind limbs was measured by placing the rat in a Perspex tube so that each hind paw was resting on a separate transducer pad. The distribution of bodyweight on each paw over 3 s was recorded and the average of three separate measurements taken. Weight readings for the left and right limbs were taken and the difference between these calculated and plotted. Measurements were taken 2 days prior to the start of the study and then on days 7, 14, 21, 28, and 35. Prior to inclusion in the study, rats were trained for 1 week to acclimatise them to the new apparatus.

Termination and histopathology {#sec2.4}
------------------------------

Animals were terminated 21 days post surgery with a rising concentration of CO~2~ and death confirmed by cervical dislocation. Knee joints were obtained for histopathological analysis by making a full thickness cut 2 cm above and below the patella. The joints were formalin fixed and decalcified on 10% formic acid prior to processing by routine vacuum assisted wax infiltration. Toluidine blue stained step-sections were evaluated for proteoglycan loss, cartilage erosion and subchondral cartilage deposits. Sections were subjectively graded for the most severe changes in cartilage morphology assessing proteoglycan loss, erosion, proliferation and fibrillation on any single section and given a score of between 0 and 4 as follows: 0 -- pathology not present, 1 -- minimal change, small foci, 2 -- mild change, up to 20% affected, 3 -- moderate change, up to 50% affected, 4 -- severe change, greater than 50% affected. The maximum score for the TIB and FEM condyles was 12 respectively, giving a total obtainable knee score of 24. Proteoglycan loss was generally associated with a loss of chondrocytes and some chondrocyte clustering. Proliferation at the joint margin only referred to proliferation at the edge of the articular cartilage plateau and not proliferation down the lateral border resulting from the operative procedure. Erosion was regarded as the frank loss of cartilage matrix not just 'shrinkage' or 'thinning'. All sections were evaluated by an experienced assessor who was blinded to the animal group in all cases.

Muscle harvest {#sec2.5}
--------------

Whole bilateral quadriceps muscle samples, inclusive of the rectus femoris, were dissected, weighed and immediately snap frozen in isopentane cooled with liquid nitrogen. Care was taken to avoid inclusion of any adipose tissue or additional muscle, most importantly the tensor fasciae latae and sartorius that are located within the dissected area.

Quadriceps muscle fibre typing {#sec2.6}
------------------------------

Quadriceps muscle fibres were classified based on the expression of myosin heavy chain (MHC) protein. In brief, quadriceps muscle samples (100 mg) were crushed to a powder under liquid nitrogen and homogenised in 5 ml of extraction buffer comprising 0.5 M NaCl, 20 mM pyrophosphate, 50 mM Tris, 1 mM ethylenediaminetetraacetic acid (EDTA), and 1 mM dithiothreitol (DTT) in distilled water, pH 8.0. Following centrifugation at 1000*g* for 10 min, 500 μl aliquots of the resulting supernatant were added to an equal volume of 87% glycerol (Fluka). Preparations were vortexed to ensure thorough mixing and stored at −20°C until required. Following total protein determination[@bib41] 50 ng protein was mixed with loading buffer (4% v/v 87% glycerol, 25 mM 1 M Tris--HCl (pH 6.8), 8% SDS and 20 mg pyronin Y, with 10% v/v beta-mercaptoethanol added prior to use). The myosin preparations were separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis as described by Mizunoya[@bib42]. Separating gels consisted of 35% v/v glycerol, 8% w/v acrylamide (bis) 49:1 (Sigma), 0.2 M Tris--HCl (pH 8.8), 0.1 M glycine, 0.4% w/v SDS, 0.1% w/v ammonium persulphate, and 0.05% v/v *N*,*N*,*N*′,*N*′-tetramethylethylenediamine (TEMED). The stacking gel consisted of 30% v/v glycerol, 4% acrylamide (bis) 49:1, 70 mM Tris--HCl (pH 6.7), 4 mM EDTA, 0.4% w/v SDS, 0.1% w/v ammonium persulphate, and 0.05% v/v TEMED. Gels were prepared the day prior to running and stored at 4°C. The lower running buffer consisted of 0.05 M Tris--HCl, 75 mM glycine, and 0.05% w/v SDS. The upper running buffer was 6× the concentration of the lower running buffer and beta-mercaptoethanol was added before use at a final concentration of 0.12%v/v. Electrophoretic separation was performed in two stages. Sample entry into the stacking gel was run at 10 mA for 40 min, the remainder of the electrophoresis was carried out at 140 V (constant voltage) for 21.3 h. Throughout the electrophoresis, the apparatus was kept in a cold room at 4°C. Following electrophoresis, the different MHC isoforms were detected by silver staining[@bib43] and analysed by semi-quantitative densitometry (Bio-Rad, FluorS) according to the manufacturer\'s instructions.

Statistical analysis {#sec2.7}
--------------------

All data are reported as means ± standard error of the mean ([s.e.m.]{.smallcaps}). Comparisons were performed using the independent samples *t*-test between two groups, or analysis of variance (ANOVA) between multiple groups. Appropriate post-hoc tests were used to test for significance, with significance accepted as *P* \< 0.05.

Results {#sec3}
=======

Clenbuterol administration increases rodent bodyweight, growth rate and quadriceps muscle mass {#sec3.1}
----------------------------------------------------------------------------------------------

Subcutaneous administration of clenbuterol at a dosage of 1.5 mg/kg/day resulted in a 35% elevation in weight gain following 14 days of treatment (*P* = \<0.001) ([Fig. 1](#fig1){ref-type="fig"}), compared to saline control treated animals. Analysis of growth rate (derived from daily weight data) revealed an initial reduction in weight during the first three doses of clenbuterol followed by an increase in growth rate (g/day gained) from dose 4 onwards (*P* = \<0.001) compared with saline treated controls ([Table I](#tbl1){ref-type="table"}). On evisceration, treated animals had visibly reduced adipose deposits and larger, more defined skeletal musculature. In addition to total bodyweight, quadriceps mass was elevated (+40%) following clenbuterol treatment (6.52 g ± 0.21) compared with saline treated controls (4.64 g ± 0.21), (*P* = \<0.001). Statistical significance was maintained when quadriceps mass was normalised to total bodyweight (*P* = 0.020).

MHC isoform protein expression was used as an index of muscle function. Our analysis showed that the rat quadriceps muscle is predominantly composed of "fast twitch" MHC, with a composition of 4.85% type I, 7.25% type IIA, 22.34% type IIX and 66.55% type IIB ([Fig. 2](#fig2){ref-type="fig"}). Clenbuterol administration exhibited an apparent 16% increase in total MHC protein expression relative to total protein (data not presented), although there was no change in the composition of the different MHC isoforms ([Table I](#tbl1){ref-type="table"}).

MNX surgery results in OA-like lesions, weight bearing perturbations and alters the MHC composition of the quadriceps muscle {#sec3.2}
----------------------------------------------------------------------------------------------------------------------------

MNX surgery was associated with a reduction in weight gain (16.92 ± 1.12%) compared with those animals undergoing the sham control procedure (24.03 ± 0.98%) *P* = 0.021 at the end of the study period ([Table II](#tbl2){ref-type="table"}). Of those animals subjected to MNX surgery, histopathological examination of the ipsilateral limbs revealed evidence of OA-like lesions, predominantly localised at the TIB condyle. Microscopically, meniscectomised tibias presented with proteoglycan and chondrocyte loss, erosion and ulceration of the articular surface, but limited evidence of subchondral degeneration. FEM condyles showed evidence of proteoglycan loss; however this was less severe than that noted on the respective TIB condyles. No FEM erosion, ulceration or subchondral degeneration was noted within the experimental timeframe ([Table III](#tbl3){ref-type="table"}). *sham operated control animals were free from OA 21 days post surgery.*

Surgery was also associated with a reduced quadriceps mass relative to bodyweight (1.60 ± 0.05) compared with those animals that underwent a sham procedure (1.69 ± 0.02) at the end of the study although this did not reach statistical significance (*P* = 0.154). Electrophoretic examination of the quadriceps muscles at 21 days post surgery was performed to examine changes in the MHC expression profile ([Fig. 2](#fig2){ref-type="fig"}). Compared to the sham control animals, MNX operated (saline pre-treated) animals exhibited an apparent 115% increase in the protein expression of the slow twitch MHC I (*P* = 0.08), numerically in lieu of fast twitch MHC IIB ([Table II](#tbl2){ref-type="table"}).

Incapacitance assessment (as a marker of weight bearing/behavioural pain) demonstrated a 50:50 load distribution between the hind limbs prior to surgery ([Fig. 3](#fig3){ref-type="fig"}). Following MNX surgery, significantly less weight was placed on the ipsilateral limb (day 14 vs day 21, day 28, day 35; *P* = \< 0.001). Weight distribution between the hind limbs of the MNX treated animals resolved over a period of 14 days post surgery, although equal distribution was not achieved within the experimental timeframe.

Clenbuterol-induced muscle hypertrophy is unable to modulate the severity of disease {#sec3.3}
------------------------------------------------------------------------------------

Animals pre-treated with clenbuterol prior to MNX were unable to maintain the previously noted increase in quadriceps mass relative to bodyweight (1.70 ± 0.02) compared to saline pre-treated meniscectomised subjects (1.60 ± 0.05) at the end of the study (*P* = 0.154). The characteristic reduction in bodyweight gain following MNX was suppressed in response to clenbuterol pre-treatment, leading to similar weight gain to those animals undergoing the sham control procedure (clenbuterol MNX: 20.16 ± 1.11%, sham control 24.03 ± 0.98%). Electrophoretic analysis of MHC isoforms demonstrated that clenbuterol pre-treatment prior to MNX suppressed the increase in MHC I protein, which was previously associated with MNX surgery, and numerically, maintained the MHC IIB complement ([Table II](#tbl2){ref-type="table"}). However, 14 days pre-treatment with the β~2~-agonist clenbuterol had no significant effect on TIB or FEM pathology 21 days post MNX compared to those animals pre-treated for 14 days with saline. Microscopically, the severity of proteoglycan and chondrocyte loss, ulceration and subchondral degeneration observed post surgery remained unaffected from the pre-treatment with clenbuterol ([Table III](#tbl3){ref-type="table"}).

Discussion {#sec4}
==========

This is the first study to report the role of the quadriceps muscle, and the effects of induced skeletal muscle hypertrophy on the severity of joint pathology in an animal model of OA. Here, we observed a trend towards increased slow, MHC I protein in the quadriceps during the induction of OA-like cartilage lesions in the rat MNX model of OA, as determined by MHC protein expression. We also observed that the gross increase in the quadriceps muscle induced by the β~2~ adrenergic agonist, clenbuterol, could not modulate the severity of joint damage or subsequent behavioural pain in this model.

The use of clenbuterol to induce skeletal muscle hypertrophy and promote lipolysis is well characterised across multiple species[@bib44]. Here, following 2 weeks of clenbuterol treatment we attained a significant increase in the quadriceps muscle mass (+40%). However, at the study endpoint, the hypertrophic effect of clenbuterol was no longer apparent in the pre-treated animals, which presented with comparable quadriceps mass to bodyweight ratios. To determine muscle fibre composition of the quadriceps, we monitored MHC protein expression. Of interest we found that although no changes to the MHC protein composition were noted in response to clenbuterol prior to surgery, subtle effects of clenbuterol on MHC protein expression were observed in the period post surgery where clenbuterol suppressed the trend towards an MNX surgery-induced increase in MHC I. Although we only noted a trend association between pre-treatment with clenbuterol and suppression of the increase in MHC I protein observed post surgery (*P* = 0.081), this is supported by several studies that report the slow to fast fibre inducing effects of clenbuterol in rodents[@bib44]. The fact that we did not observe these changes in the pre-treatment period may be due to the length of drug exposure and/or the muscle studied. The latter may be related to the natural distribution of MHC protein isoforms within the quadriceps muscle which comprises over 85% fast MHC IIX/MHC IIB, and less than 15% slower MHC I/MHC IIA. Such a high baseline complement of fast MHC is likely to reduce the impact of a drug such as clenbuterol with regards to its effect in inducing slow to fast fibre type transitions. Previous studies noting such changes were often conducted over a longer timeframe and tended to study the slow twitch soleus muscle, which is particularly susceptible to fibre type shifts.

As previously noted, MNX surgery was associated with a trend towards increased MHC I, indicative of a switch towards a slower more oxidative and fatigue resistant muscle type, more commonly associated with postural, anti-gravity muscles[@bib45]. Such changes in muscle fibre type following MNX may have important implications for rehabilitation, in particular the type of muscle strengthening program recommended. One possible reason for this change in MHC composition in response to MNX surgery might be that it is a physiological attempt to increase stability of the operated joint by increasing the complement of fatigue resistant, slow muscle fibres that surround it. A further possibility is that surgery-induced changes in weight bearing led to disuse atrophy of fast MHC IIB fibres, resulting in an increase in the relative proportion of slower MHC I fibres as noted previously[@bib46]. We must stress however, that only mild changes to weight bearing were noted (∼4%) and it is unclear whether such modest perturbations are capable of inducing changes to the relative distribution of MHC.

A number of previous studies suggest that modulating muscle function through exercise may have an impact on the development and severity of OA in humans; therefore we must consider why no effect was noted in this experimental model. The experimental approach chosen in the present study was to dose with clenbuterol for up to 2 weeks prior to surgical induction of OA, but to stop administration immediately after surgery. This approach avoided any potential confounding factors of direct clenbuterol action at the joint or direct cardiovascular effects and in our opinion allowed us to better mimic the physiological impact of a hypertrophic quadriceps muscle on OA severity. However, although clenbuterol resulted in marked increases in quadriceps mass during the pre-treatment period, this effect was not maintained throughout the time course of the study and may explain the lack of effect on OA severity reported in the study. Another possibility might be the agent of choice we used in this study to induce muscle hypertrophy. Although clenbuterol is effective in this regard, it also leads to an overall increase in animal bodyweight due to the induction of lean mass, a concurrent decline in fat mass and the relatively high mass of skeletal muscle compared to that of adipose tissue[@bib47; @bib48]. It is well known that weight is a risk factor for knee OA[@bib49]. Moreover, bodyweight has been associated with the severity of OA in the Dunkin Hartley guinea pig where a 28% reduction in bodyweight led to a marked 40% decrease in OA severity[@bib50]. By inference, it is therefore possible that this increased bodyweight in our clenbuterol treated animals compared to the control animals, at the time of induction, may have negated any potential beneficial effect of a strengthened quadriceps, and thus explains the lack of positive modulation noted during this study. A further possibility is that muscle mass is not the sole or the major determinant with regards to the role of muscles in OA. Instead, it is likely that it is the coordinate modulation of several muscle parameters such as muscle fibre type composition and size of motor units recruited during exercise that together with mass, are key in eliciting an impact on OA pathology.

In addition it is also important to note that clenbuterol has greater hypertrophic effects on slow twitch muscles compared with faster twitch muscles[@bib35; @bib36]. In the intact knee, agonist force is generated by the quadriceps muscle in tandem with antagonist force generation by the hamstrings producing joint stability[@bib51]. If one considers the quadriceps/hamstrings balance (Q/H ratio) and that anabolic steroid-induced hypertrophy might elicit a greater strength increases in leg flexion over leg extension[@bib52], it is possible that clenbuterol administration induced skeletal muscle hypertrophy disproportionately across the various muscles surrounding the knee joint, disrupting the fine balance of agonist and antagonist forces, leading to decreased joint stability. This could have a detrimental effect on the formation of joint pathology in a similar way to that observed in man with joint instability due to joint mal-alignments[@bib53].

In summary, these findings suggest that clenbuterol-induced gross increases in skeletal musculature do not modulate the severity of OA in the rodent MNX model. We propose that animal models of OA that better mimic the human condition in terms of initiation and progression rates, and the use of pharmacological agents that more selectively target the Q/H ratio without additional weight gain, may provide a more suitable platform on which to observe subtle changes in disease progression brought about through modulating skeletal muscle function.
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![The effect of subcutaneous administration of clenbuterol (1.5 mg/kg/day) on bodyweight. Male Lewis rats were randomly assigned to one of two experimental groups receiving daily subcutaneous doses of clenbuterol 1.5 mg/kg/day (*n* = 5) or saline control (*n* = 5). Cumulative weight changes were recorded daily for both clenbuterol (black lines) and saline treated (grey lines) subjects during a 14-day pre-treatment phase. Data are mean cumulative percentage ± [s.e.m]{.smallcaps}.](gr1){#fig1}

![Electrophoretic separation of the various myosin heavy chain protein isoforms in rat skeletal muscle. (A) Silver stained electrophoretic separation demonstrating the presence of four well-defined bands in the rat quadriceps (Lane 1). Lanes 2 and 3 contain control material from rat diaphragm and soleus respectively with known MHC protein expression profiles. (B) Silver stained electrophoretic separation demonstrating the presence of four well-defined bands in the rat quadriceps in response to various interventions.](gr2){#fig2}

![The effects of MNX surgery and treatment regime on weight bearing. The effect of MNX surgery on weight bearing was assessed in both saline (grey line; *n* = 10) and clenbuterol (black line; *n* = 10) pre-treated meniscectomised animals. Two days prior to inclusion in the study, animals were acclimatised to the incapacitance equipment (d-2). Animals were pre-treated from day 1 through day 14 and surgery performed on day 15. Prior to surgery and during the 21-day development phase immediately post surgery, weight distribution was assessed using an incapacitance meter (Linton, UK) and data expressed as the percentage of total weight distributed to the operated limb ± [s.e.m]{.smallcaps}.](gr3){#fig3}

###### 

The effect of subcutaneous administration of clenbuterol (1.5 mg/kg/day) on quadriceps muscle parameters and MHC protein expression

  Parameter                         Saline         Clenbuterol    *P* value
  --------------------------------- -------------- -------------- -----------
  Bodyweight gain (%)               8.37 ± 0.62    11.46 ± 1.94   \<0.001
  Growth rate (g/day)               1.47 ± 0.10    4.04 ± 0.48    \<0.001
  Quadriceps mass (g)               4.64 ± 0.21    6.52 ± 0.21    \<0.001
  Quadriceps mass (% bodyweight)    1.60 ± 0.08    2.01 ± 0.12    0.020
  \% MHC I                          4.84 ± 0.93    4.68 ± 0.92    0.988
  \% MHC IIa                        7.25 ± 2.83    6.29 ± 2.59    0.963
  \% MHC IIx                        22.34 ± 6.50   27.44 ± 2.88   0.631
  \% MHC IIb                        66.55 ± 7.44   62.77 ± 4.21   0.586
  Ratio \[I + IIA\]/\[IIX + IIB\]   0.13 ± 0.05    0.147 ± 0.05   0.393

Following 14 days of pre-treatment with either clenbuterol (1.5 mg/kg/day) or saline, protein extracts were prepared from quadriceps specimens and applied to an SDS PAGE gel. The different MHC protein isoforms were detected by silver staining. The % myosin data are mean densitometric units expressed as a percentage of the total MHC signal ± [s.e.m]{.smallcaps}.

###### 

The effects of MNX surgery and pre-treatment with clenbuterol (1.5 mg/kg/day) on quadriceps muscle parameters and MHC protein expression

  Parameter                         Sham                                            Saline MNX     Clenbuterol MNX   *P* value
  --------------------------------- ----------------------------------------------- -------------- ----------------- -----------
  Bodyweight gain (%)               24.03 ± 0.98[∗](#tblfn1){ref-type="table-fn"}   16.92 ± 1.12   20.16 ± 1.11      0.021
  Quadriceps mass (g)               5.91 ± 1.19                                     5.32 ± 1.72    5.60 ± 1.57       0.099
  Quadriceps mass (% bodyweight)    1.69 ± 0.02                                     1.60 ± 0.05    1.70 ± 0.02       0.154
  MHC I                             3.55 ± 0.99                                     7.61 ± 2.15    2.68 ± 0.99       0.081
  MHC IIa                           7.27 ± 4.24                                     11.18 ± 1.86   11.69 ± 2.20      0.545
  MHC IIx                           24.02 ± 2.52                                    23.54 ± 2.21   22.14 ± 3.16      0.892
  MHC IIb                           68.10 ± 5.37                                    60.31 ± 4.07   67.53 ± 3.83      0.359
  Ratio \[I + IIA\]/\[IIX + IIB\]   0.09 ± 0.04                                     0.18 ± 0.04    0.15 ± 0.03       0.359

Following 14 days pre-treatment with either the β~2~-agonist clenbuterol or saline control, animals were sub-divided into those that underwent MNX surgery (saline pre-treated *n* = 10; clenbuterol pre-treated *n* = 10) and those that underwent a sham control surgical procedure (saline pre-treated *n* = 5). Electrophoretic examination of the quadriceps muscles at 21 days post MNX surgery was performed to examine changes in the MHC protein expression profile. Protein extracts were prepared from quadriceps specimens and applied to an SDS PAGE gel and the different MHC isoforms detected by silver staining. Data are mean densitometric units expressed as a percentage of the total MHC signal ± [s.e.m]{.smallcaps}.

Saline MNX significantly different from sham procedure *P* = \<0.05.

###### 

The effects of MNX and treatment regime on joint histopathology

  Parameter                             Saline MNX    Clenbuterol MNX   *P* value
  ------------------------------------- ------------- ----------------- -----------
  Proteoglycan/chondrocyte loss (TIB)   1.90 ± 0.18   2.10 ± 0.23       0.491
  Erosion/ulceration (TIB)              1.10 ± 0.35   1.30 ± 0.34       0.663
  Subchondral degeneration (TIB)        0.20 ± 0.13   0.50 ± 0.27       0.485
  Proteoglycan/chondrocyte loss (FEM)   0.40 ± 0.22   0.80 ± 0.25       0.202
  Erosion/ulceration (FEM)              0 ± 0         0 ± 0             --
  Subchondral degeneration (FEM)        0 ± 0         0 ± 0             --
  Total pathology                       3.20 ± 0.59   3.90 ± 0.73       0.398

Of those animals subjected to MNX surgery (Saline MNX (*n* = 10), Clen MNX (*n* = 10)), histopathological examination was performed by microscopically evaluating toluidine stained step coronal joint sections for evidence of OA on both the TIB and FEM condyles. Data are mean pathology score ± [s.e.m]{.smallcaps}. *P* values refer to differences in OA severity between saline and clenbuterol pre-treated subjects as determined by Mann--Whitney analysis.
